Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Lilly's new diet drug comes up short in trials
Posted
August 8, 2025
Views
2,010
Likes
23
Comments
1
Engagement
1.19%
August 8, 2025
2,010
23
1
1.19%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
1:23Now PlayingA new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegovy, and Ozempic.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
